Topics
May/June 2017 | Cover Focus: A Better Tomorrow
Introduction
Karen Roman, Editor-in-Chief
October 12, 2026
ANI Pharmaceuticals Reports Sustained 24-Month Efficacy of Iluvien in Phase 4 SYNCHRONICITY trial
Merck’s Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME
American Academy of Ophthalmology Announces 2026 Award Recipients at Annual Conference
Brent Saunders Departs as CEO of Bausch + Lomb
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Free Print Subscription
Email Newsletter
Conference Calendar
